Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Growth Projections 2023-2032: DelveInsight Analysis | Eidos, Corino, Prothena, Ionis Pharma, AstraZeneca, Novo Nordisk

DelveInsight's "Transthyretin Amyloid Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Transthyretin Amyloid Cardiomyopathy, historical and forecasted epidemiology as well as the Transthyretin Amyloid Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Transthyretin Amyloid Cardiomyopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Transthyretin Amyloid Cardiomyopathy Market Forecast
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Transthyretin Amyloid Cardiomyopathy Market Report:
• The Transthyretin Amyloid Cardiomyopathy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In June 2024, AMVUTTRA achieved its primary and secondary endpoints in the Phase III HELIOS-B study (NCT04153149), showing significant efficacy compared to placebo in patients with ATTR-CM. Alnylam Pharmaceuticals intends to submit a supplemental new drug application (sNDA) for AMVUTTRA as a potential treatment for ATTR-CM, utilizing a priority review voucher.
• According to AstraZeneca's H1 2024 clinical trial appendix, data from the eplontersen (CARDIO-TTRansform study, NCT04136171) is expected to be available in 2025 or later.
• ATTR-CM is more commonly observed in males (61.3%) compared to females (38.7%), whereas wild-type ATTR-CM is more prevalent in females (53.7%) than in males (46.3%).
• According to ICER, the exact prevalence of ATTR-CM in the U.S. population is uncertain, with estimates ranging between 50,000 and 200,000, and possibly exceeding these figures.
• The study by Damy et al. (2023), titled "Transthyretin Cardiac Amyloidosis in Continental Western Europe: An Insight Through the Transthyretin Amyloidosis Outcomes Survey (THAOS)," reported that among the overall registry, 14.9% (210 subjects) presented with a 'cardiac' clinical phenotype, while 21.1% (298 subjects) exhibited a mixed 'cardiac + neurologic' presentation.
• According to Ney et al. (2023), the prevalence in Germany rose from 15.5 cases per 100,000 person-years in 2009 to 47.6 cases per 100,000 person-years in 2018.
• Key Transthyretin Amyloid Cardiomyopathy Companies: Ionis Pharmaceuticals and AstraZeneca, BridgeBio, NeuraImmune Therapeutics, and others
• Key Transthyretin Amyloid Cardiomyopathy Therapies: WAINUA (eplontersen), Acoramidis (AG10), NI006, and others
• The Transthyretin Amyloid Cardiomyopathy epidemiology based on gender analyzed that FAP is the most affected type-specific hATTR in the US
• The Transthyretin Amyloid Cardiomyopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Transthyretin Amyloid Cardiomyopathy pipeline products will significantly revolutionize the Transthyretin Amyloid Cardiomyopathy market dynamics.

Transthyretin Amyloid Cardiomyopathy Overview
Transthyretin Amyloid Cardiomyopathy (ATTR) is a rare, progressive disease caused by the misfolding and accumulation of transthyretin (TTR) protein as amyloid deposits in various organs and tissues. It can be hereditary (hATTR) due to TTR gene mutations or acquired (wild-type ATTR) without genetic mutations. The condition primarily affects the heart (causing cardiomyopathy) and nerves (leading to polyneuropathy), resulting in symptoms like heart failure, neuropathic pain, weakness, and autonomic dysfunction. Diagnosis involves genetic testing, imaging, and biopsy. Treatment includes TTR stabilizers, gene-silencing therapies, and, in severe cases, organ transplantation to manage symptoms and slow disease progression.

Get a Free sample for the Transthyretin Amyloid Cardiomyopathy Market Report:
https://www.delveinsight.com/report-store/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Transthyretin Amyloid Cardiomyopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Transthyretin Amyloid Cardiomyopathy Epidemiology Segmentation:
The Transthyretin Amyloid Cardiomyopathy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Transthyretin Amyloid Cardiomyopathy
• Prevalent Cases of Transthyretin Amyloid Cardiomyopathy by severity
• Gender-specific Prevalence of Transthyretin Amyloid Cardiomyopathy
• Diagnosed Cases of Episodic and Chronic Transthyretin Amyloid Cardiomyopathy

Download the report to understand which factors are driving Transthyretin Amyloid Cardiomyopathy epidemiology trends @ Transthyretin Amyloid Cardiomyopathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Transthyretin Amyloid Cardiomyopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Transthyretin Amyloid Cardiomyopathy market or expected to get launched during the study period. The analysis covers Transthyretin Amyloid Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Transthyretin Amyloid Cardiomyopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Transthyretin Amyloid Cardiomyopathy Therapies and Key Companies
• WAINUA (eplontersen): Ionis Pharmaceuticals and AstraZeneca
• Acoramidis (AG10): BridgeBio
• NI006: NeuraImmune Therapeutics

Discover more about therapies set to grab major Transthyretin Amyloid Cardiomyopathy market share @ Transthyretin Amyloid Cardiomyopathy Treatment Market
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Transthyretin Amyloid Cardiomyopathy Market Strengths
• Tafamidis has been shown to improve survival rates and reduce hospitalization for cardiovascular issues in patients with ATTR-CM, particularly when administered early in the disease process.
• Recent developments in non-invasive imaging techniques, such as technetium Tc 99m pyrophosphate scintigraphy, have enhanced the ability to diagnose ATTR-CM earlier. This allows for timely intervention and management of the disease.

Transthyretin Amyloid Cardiomyopathy Market Opportunities
• There is a compelling medical need to develop therapies for ATTR-CM, as there are currently only two approved treatments available for this condition.
• Implementing targeted screening programs for at-risk populations can lead to earlier identification of ATTR-CM. This includes using clinical scoring systems to identify patients with heart failure who may benefit from further diagnostic testing.

Scope of the Transthyretin Amyloid Cardiomyopathy Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Transthyretin Amyloid Cardiomyopathy Companies: Ionis Pharmaceuticals and AstraZeneca, BridgeBio, NeuraImmune Therapeutics, and others
• Key Transthyretin Amyloid Cardiomyopathy Therapies: WAINUA (eplontersen), Acoramidis (AG10), NI006, and others
• Transthyretin Amyloid Cardiomyopathy Therapeutic Assessment: Transthyretin Amyloid Cardiomyopathy current marketed and Transthyretin Amyloid Cardiomyopathy emerging therapies
• Transthyretin Amyloid Cardiomyopathy Market Dynamics: Transthyretin Amyloid Cardiomyopathy market drivers and Transthyretin Amyloid Cardiomyopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Transthyretin Amyloid Cardiomyopathy Unmet Needs, KOL's views, Analyst's views, Transthyretin Amyloid Cardiomyopathy Market Access and Reimbursement

To know more about Transthyretin Amyloid Cardiomyopathy companies working in the treatment market, visit @ Transthyretin Amyloid Cardiomyopathy Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/transthyretin-amyloid-cardiomyopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Transthyretin Amyloid Cardiomyopathy Market Report Introduction
2. Executive Summary for Transthyretin Amyloid Cardiomyopathy
3. SWOT analysis of Transthyretin Amyloid Cardiomyopathy
4. Transthyretin Amyloid Cardiomyopathy Patient Share (%) Overview at a Glance
5. Transthyretin Amyloid Cardiomyopathy Market Overview at a Glance
6. Transthyretin Amyloid Cardiomyopathy Disease Background and Overview
7. Transthyretin Amyloid Cardiomyopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Transthyretin Amyloid Cardiomyopathy
9. Transthyretin Amyloid Cardiomyopathy Current Treatment and Medical Practices
10. Transthyretin Amyloid Cardiomyopathy Unmet Needs
11. Transthyretin Amyloid Cardiomyopathy Emerging Therapies
12. Transthyretin Amyloid Cardiomyopathy Market Outlook
13. Country-Wise Transthyretin Amyloid Cardiomyopathy Market Analysis (2019-2032)
14. Transthyretin Amyloid Cardiomyopathy Market Access and Reimbursement of Therapies
15. Transthyretin Amyloid Cardiomyopathy Market Drivers
16. Transthyretin Amyloid Cardiomyopathy Market Barriers
17. Transthyretin Amyloid Cardiomyopathy Appendix
18. Transthyretin Amyloid Cardiomyopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Transthyretin Amyloid Cardiomyopathy Pipeline https://www.delveinsight.com/report-store/transthyretin-amyloid-cardiomyopathy-attr-cm-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Transthyretin Amyloid Cardiomyopathy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Transthyretin Amyloid Cardiomyopathy market. A detailed picture of the Transthyretin Amyloid Cardiomyopathy pipeline landscape is provided, which includes the disease overview and Transthyretin Amyloid Cardiomyopathy treatment guidelines.

Latest Reports by DelveInsight
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.